Systemic Efficacy
DISEASE PROGRESSION
At the data cutoff, 50 patients (62.5%) in the gefitinib plus chemotherapy group and 60 patients (74.1%) in the gefitinib group had systemic disease progression. The median PFS was 16.3 months (95% CI, 14.4-18.2 months) in the gefitinib plus chemotherapy group vs 9.5 months (95% CI, 8.3-10.8 months) in the gefitinib group (HR, 0.39; 95% CI, 0.27-0.58; At the data cutoff, 59.0% of patients (41 patients in the gefitinib plus chemotherapy group and 54 patients in the gefitinib group) had died. The median OS was significantly longer in the gefitinib plus chemotherapy group than in the gefitinib group (35.0; 95% CI, 28.3-41.7 vs 28.9; 95% CI, 23.2-34.5 months; HR, 0.65; 95% CI, 0.43-0.99; 